Morgan Stanley has upgraded Vir Biotechnology ( VIR, Financial) and uplifted its price target for the stock to $20 from ...

Global brokerage Goldman Sachs on Thursday lowered its target price for Reliance Industries Ltd (RIL), while maintaining 'buy' rating for the diversified group. The brokerage reduced RIL's target ...

Experian's (LON:EXPN) outlook for margin expansion is "robust" and underpins the potential for sustained organic growth, according to analysts at Morgan Stanley (NYSE:MS).

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

Indian benchmark equity indices, Sensex and Nifty50, opened lower on Thursday, reflecting negative signals from global ...

Two Morgan Stanley analysts have outlined bull-case target prices that imply substantial upside for Datadog and Arm ...

Morgan Stanleys Chief US Equity Strategist, Mike Wilson, forecasts a volatile first half of 2025, with recovery prospects ...

Reliance Industries' stock valuation hits a 3-year low, offering a strong risk-reward opportunity. Analysts foresee growth in ...

Fintel reports that on January 8, 2025, Morgan Stanley upgraded their outlook for NetEase (OTCPK:NETTF) from Equal-Weight to ...

Morgan Stanley closed $8.38 short of its 52-week high ($136.24), which the company achieved on November 25th.

The bulk of Morgan Stanley's new managing directors, or 46%, work for the investment bank.

Morgan Stanley (MS) stock saw a decline, ending the day at $126.88 which represents a decrease of $-1.76 or -1.37% from the prior close of $128.64. The stock opened at $129.65 and touched a low of ...